Avandia increases some cardiovascular risks but not others
This article was originally published in Scrip
Executive Summary
A large-scale postmarketing study of GlaxoSmithKline's thiazolidinedione Avandia (rosiglitazone) has challenged some beliefs that it increases the risk of cardiac death, but confirms that the drug more than doubles the risk of heart failure.